Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM35M8J)

• Drug Name: Thioridazine Drug Info
• Synonyms: Aldazine; Mallorol; Malloryl; Meleril; Mellaril; Mellarit; Mellerets; Mellerette; Melleretten; Melleril; Melleryl; Metlaril; Novoridazine; Orsanil; Ridazine; Sonapax; Stalleril; Thioridazin; Thioridazinum; Thioxidazine; Tioridazin; Tioridazina; Thioridazine Hcl; Thioridazine Hcl Intensol; Thioridazine prolongatum; Thoridazine hydrochloride; Dl-Thioridazine; Mellaril (TN); Mellaril-S; Melleril (liquid); Novoridazine (TN); TP-21; Thioridazine, prolongatum; Thioridazinum [INN-Latin]; Thioril (TN); Tioridazina [INN-Spanish]; Mellaril-S (TN); Thioridazine (USP/INN); Thioridazine [USAN:INN:BAN]; Mellaril (*Hydrochloride*); (+-)-Thioridazine; 10-(2-(1-Methyl-2-piperidyl)ethyl)-2-(methylthio)phenothiazine; 10-[2-(1-methyl-2-piperidyl)ethyl]-2-methylsulfanyl-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylsulfanyl)-10H-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylthio)-10H-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfanylphenothiazine; 2-Methylmercapto-10-(2-(N-methyl-2-piperidyl)ethyl)phenothiazine; 3-Methylmercapto-N-(2'-(N-methyl-2-piperidyl)ethyl)phenothiazine

Indication

Disease Entry	ICD 11	Status	REF
Schizophrenia	6A20	Approved	[1]

• Therapeutic Class: Antipsychotic Agents
• Cross-matching ID:
  PubChem CID: 5452
  ChEBI ID: CHEBI:9566
  CAS Number: CAS 50-52-2
  TTD Drug ID: DM35M8J
  VARIDT Drug ID: DR00785
  INTEDE Drug ID: DR1581
  ACDINA Drug ID: D00672

Molecule-Related Drug Atlas

Drug(s) Targeting Dopamine D2 receptor (D2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[11]
Haloperidol	DM96SE0	Delirium		Approved	[12]
Perphenazine	DMA4MRX	Schizophrenia	6A20	Approved	[13]
Perazine	DM2AOTZ	Psychotic disorder	6A20-6A25	Approved	[14]
Domperidone	DMBDPY0	Gastrointestinal disease	DE2Z	Approved	[15]
Levodopa	DMN3E57	Parkinson disease	8A00.0	Approved	[16]
Quetiapine	DM1N62C	Anorexia nervosa cachexia	6B80	Approved	[17]
Pimozide	DMW83TP	Schizophrenia	6A20	Approved	[18]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[19]
Iloperidone	DM6AUFY	Schizophrenia	6A20	Approved	[20]

Drug(s) Transported By P-glycoprotein 1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[21]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[22]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[23]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[24]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[23]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[23]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[25]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[23]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[26]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[27]

Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[28]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[29]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[30]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[31]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[32]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[33]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[34]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[35]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[36]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[37]

Drug(s) Metabolized By Mephenytoin 4-hydroxylase (CYP2C19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[38]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[39]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[40]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[41]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[42]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[43]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[44]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[45]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[46]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[47]

Drug(s) Affected By Cytochrome P450 2C19 (CYP2C19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[48]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[49]
Chloramphenicol	DMFXEWT	Bacterial infection	1A00-1C4Z	Approved	[50]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[51]
Pentamidine	DMHZJCG	African trypanosomiasis	1F51	Approved	[52]
Stiripentol	DMMSDOY	Dravet syndrome	8A61.11	Approved	[53]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[52]
Desipramine	DMT2FDC	Attention deficit hyperactivity disorder	6A05.Z	Approved	[54]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[55]
Clobazam - Lundbeck	DMW1OQ0	Anxiety disorder	6B00-6B0Z	Approved	[56]

Drug(s) Affected By D(2) dopamine receptor (DRD2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Droperidol	DM0DXA8	Nausea	MD90	Approved	[55]
Zuclopenthixol	DMKYD5N	Schizophrenia	6A20	Approved	[55]
Meglitinides	DM1OFHN	Type-2 diabetes	5A11	Approved	[57]
Sulpiride	DMF54ZG	Schizophrenia	6A20	Approved	[58]
Risperidone	DMN6DXL	Bipolar I disorder		Approved	[59]
Olanzapine	DMPFN6Y	Bipolar depression		Approved	[60]
Methamphetamine	DMPM4SK	Anxiety		Approved	[61]
Bromocriptine	DMVE3TK	Acromegaly	5A60.0	Approved	[62]
Fluphenazine	DMIT8LX	Psychotic disorder	6A20-6A25	Approved	[63]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[64]

Drug(s) Affected By G protein-activated inward rectifier potassium channel 1 (KCNJ3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[55]
Haloperidol	DM96SE0	Delirium		Approved	[55]
Pimozide	DMW83TP	Schizophrenia	6A20	Approved	[55]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[65]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[66]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[67]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[68]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[69]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[70]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[71]

Drug(s) Affected By Cytochrome P450 2E1 (CYP2E1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fomepizole	DM6VOWQ	Athylene glycol or methanol poisoning	NE61	Approved	[72]
Ademetionine	DMYQDBO	Hepatic fibrosis	DB93.0	Approved	[73]
Theophylline	DMRJFN9	Bronchitis	CA20	Approved	[55]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[74]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[75]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[76]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[77]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[78]
Didanosine	DMI2QPE	Human immunodeficiency virus infection	1C62	Approved	[55]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[79]

Drug(s) Affected By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Eplerenone	DMF0NQR	Heart failure	BD10-BD13	Approved	[80]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[48]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[81]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[49]
Proguanil	DMBL79I	Malaria	1F40-1F45	Approved	[52]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[52]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[82]
Nelfinavir mesylate	DMFX6G8	N. A.	N. A.	Approved	[83]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[84]
Axitinib	DMGVH6N	Renal cell carcinoma	2C90	Approved	[85]

Drug(s) Affected By Cytochrome P450 2A6 (CYP2A6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tegafur	DM31ZQM	Solid tumour/cancer	2A00-2F9Z	Approved	[86]
Methoxsalen	DME8FZ9	Cutaneous T-cell lymphoma	2B01	Approved	[87]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[88]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[89]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[76]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[90]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[91]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[92]
Letrozole	DMH07Y3	Estrogen-receptor positive breast cancer		Approved	[93]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[94]

Drug(s) Affected By Cytochrome P450 2C9 (CYP2C9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[48]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[95]
Dapsone	DM4LT8A	Acne vulgaris	ED80	Approved	[52]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[49]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[51]
Zafirlukast	DMHNQOG	Asthma	CA23	Approved	[96]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[52]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[97]
Fluconazole	DMOWZ6B	Cryptococcal meningitis		Approved	[49]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[52]

Drug(s) Affected By Phytanoyl-CoA dioxygenase, peroxisomal (PHYH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[7]
Ofloxacin	DM0VQN3	Acute gonococcal cervicitis		Approved	[7]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[98]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[99]
Clarithromycin	DM4M1SG	Acute maxillary sinusitis		Approved	[7]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[7]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[100]
Sulfamethoxazole	DMB08GE	Acute otitis media	AB00	Approved	[7]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[92]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[101]

Drug(s) Affected By Nuclear protein 1 (NUPR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[102]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[7]
Ofloxacin	DM0VQN3	Acute gonococcal cervicitis		Approved	[6]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[103]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[7]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[104]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[7]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[105]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[6]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[6]

Drug(s) Affected By Alpha-1-antichymotrypsin (SERPINA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[7]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[106]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[103]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[7]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[107]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[7]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[108]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[108]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[7]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[109]

Drug(s) Affected By Serine protease hepsin (HPN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[7]
Selenium	DM25CGV	N. A.	N. A.	Approved	[110]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[7]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[104]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[7]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[6]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[7]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[111]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[100]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[78]

Drug(s) Affected By Fatty acid-binding protein, liver (FABP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[7]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[112]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[103]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[7]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[98]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[104]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[7]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[113]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[6]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[7]

Drug(s) Affected By Solute carrier family 2, facilitated glucose transporter member 3 (SLC2A3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
2-deoxyglucose	DMIAHVU	Solid tumour/cancer	2A00-2F9Z	Approved	[114]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[115]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[7]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[103]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[7]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[116]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[104]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[7]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[117]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[118]

Drug(s) Affected By Lanosterol synthase (LSS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[7]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[119]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[7]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[104]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[7]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[120]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[121]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[6]
Clarithromycin	DM4M1SG	Acute maxillary sinusitis		Approved	[7]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[7]

Drug(s) Affected By Inhibin beta E chain (INHBE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[7]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[103]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[7]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[104]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[7]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[121]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[6]
Clarithromycin	DM4M1SG	Acute maxillary sinusitis		Approved	[7]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[122]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[6]

Drug(s) Affected By AP-1 complex subunit sigma-1A (AP1S1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[123]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[104]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[7]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[6]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[124]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[100]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[125]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[101]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[103]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[6]

Drug(s) Affected By Transgelin (TAGLN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[7]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[126]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[103]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[7]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[127]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[104]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[7]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[128]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[103]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[129]

Drug(s) Affected By Fibronectin type III domain-containing protein 4 (FNDC4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[7]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[7]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[7]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[6]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[7]
Haloperidol	DM96SE0	Delirium		Approved	[6]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[100]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[78]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[7]
Pentamidine	DMHZJCG	African trypanosomiasis	1F51	Approved	[7]

Drug(s) Affected By Protein DEPP1 (DEPP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[7]
Ofloxacin	DM0VQN3	Acute gonococcal cervicitis		Approved	[6]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[130]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[7]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[104]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[7]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[131]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[6]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[6]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[7]

Drug(s) Affected By Asparagine synthetase (ASNS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[132]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[7]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[133]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[7]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[134]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[135]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[7]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[136]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[99]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[135]

Drug(s) Affected By Acid ceramidase (ASAH1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[7]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[137]
Ofloxacin	DM0VQN3	Acute gonococcal cervicitis		Approved	[6]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[138]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[7]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[104]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[7]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[139]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[6]
Clarithromycin	DM4M1SG	Acute maxillary sinusitis		Approved	[7]

Drug(s) Affected By Nuclear receptor subfamily 0 group B member 2 (NR0B2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Calcipotriol	DM03CP7	Psoriasis	EA90	Approved	[140]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[7]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[141]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[142]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[119]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[7]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[143]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[104]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[7]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[144]

Drug(s) Affected By Lysophospholipase D GDPD3 (GDPD3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[7]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[103]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[7]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[6]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[7]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[145]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[146]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[146]
Haloperidol	DM96SE0	Delirium		Approved	[6]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[147]

Drug(s) Affected By Prolactin (PRL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[148]
Ranitidine	DM0GUSX	Gastric ulcer	DA60	Approved	[149]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[150]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[151]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[98]
Naloxone	DM3FXMA	Narcotic depression	6A7Z	Approved	[152]
Aripiprazole	DM3NUMH	Bipolar I disorder		Approved	[153]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[154]
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[155]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[156]

Drug(s) Affected By Cellular tumor antigen p53 (TP53)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[157]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[98]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[158]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[159]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[160]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[161]
Floxuridine	DM04LR2	Colorectal cancer	2B91.Z	Approved	[162]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[163]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[164]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[165]

Drug(s) Affected By Corticoliberin (CRH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[106]
Meglitinides	DM1OFHN	Type-2 diabetes	5A11	Approved	[10]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[10]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[166]
Haloperidol	DM96SE0	Delirium		Approved	[10]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[167]
Terbutaline	DMD4381	Asthma	CA23	Approved	[168]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[10]
Pioglitazone	DMKJ485	Amyotrophic lateral sclerosis	8B60.0	Approved	[169]
Risperidone	DMN6DXL	Bipolar I disorder		Approved	[10]

Drug(s) Affected By Cyclin-dependent kinase 4 (CDK4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Palbociclib	DMD7L94	Breast cancer	2C60-2C65	Approved	[170]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[171]
Selenium	DM25CGV	N. A.	N. A.	Approved	[172]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[173]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[174]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[175]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[176]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[136]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[99]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[177]

Drug(s) Affected By G1/S-specific cyclin-D1 (CCND1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indomethacin	DMSC4A7	Bursitis		Approved	[178]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[179]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[180]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[181]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[182]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[183]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[184]
Selenium	DM25CGV	N. A.	N. A.	Approved	[110]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[185]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[186]

Drug(s) Affected By M-phase inducer phosphatase 1 (CDC25A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[187]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[188]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[189]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[190]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[136]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[99]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[191]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[192]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[193]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[194]

Drug(s) Affected By Cyclin-dependent kinase inhibitor 1 (CDKN1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[195]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[196]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[197]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[198]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[183]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[199]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[200]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[201]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[202]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[189]

Drug(s) Affected By Caspase-3 (CASP3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[203]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[204]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[205]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[160]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[206]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[207]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[208]
Mannitol	DMSCDY9	Bronchiectasis	CA24	Approved	[209]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[210]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[211]

Drug(s) Affected By Cyclin-dependent kinase inhibitor 2A (CDKN2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[187]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[123]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[201]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[212]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[213]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[158]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[214]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[215]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[216]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[78]

Drug(s) Affected By Potassium voltage-gated channel subfamily H member 2 (KCNH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metoclopramide	DMFA5MY	Nausea	MD90	Approved	[217]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[218]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[219]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[220]
Clarithromycin	DM4M1SG	Acute maxillary sinusitis		Approved	[220]
Disopyramide	DM5SYZP	Long QT syndrome	BC65.0	Approved	[221]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[222]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[223]
Dofetilide	DMPN1TW	Sinus rhythm disorder	BC9Y	Approved	[224]
Flecainide	DMSQDLE	Tachyarrhythmias	BC71	Approved	[220]

Drug(s) Affected By Eukaryotic translation initiation factor 4E-binding protein 1 (EIF4EBP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[225]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[185]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[226]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[227]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[145]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[228]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[229]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[100]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[230]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[101]

Drug(s) Affected By D(3) dopamine receptor (DRD3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Haloperidol	DM96SE0	Delirium		Approved	[231]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[232]
Risperidone	DMN6DXL	Bipolar I disorder		Approved	[233]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[234]
Methamphetamine	DMPM4SK	Anxiety		Approved	[235]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[236]
Droperidol	DM0DXA8	Nausea	MD90	Approved	[55]
Fluphenazine	DMIT8LX	Psychotic disorder	6A20-6A25	Approved	[55]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[55]
Trifluoperazine	DMKBYWI	Anxiety		Approved	[55]

Drug(s) Affected By D(4) dopamine receptor (DRD4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[237]
Haloperidol	DM96SE0	Delirium		Approved	[238]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[78]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[239]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[240]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[241]
Methamphetamine	DMPM4SK	Anxiety		Approved	[242]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[243]
Droperidol	DM0DXA8	Nausea	MD90	Approved	[55]
Fluphenazine	DMIT8LX	Psychotic disorder	6A20-6A25	Approved	[55]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Antagonist	[2]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[3]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[4]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[5]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Acid ceramidase (ASAH1)	OT1DNGXL	ASAH1_HUMAN	Gene/Protein Processing	[6]
Alpha-1-antichymotrypsin (SERPINA3)	OT9BP2S0	AACT_HUMAN	Gene/Protein Processing	[7]
AP-1 complex subunit sigma-1A (AP1S1)	OTQ2H8DN	AP1S1_HUMAN	Gene/Protein Processing	[7]
Asparagine synthetase (ASNS)	OT8R922G	ASNS_HUMAN	Gene/Protein Processing	[6]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Gene/Protein Processing	[8]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Gene/Protein Processing	[9]
Corticoliberin (CRH)	OT2MOC4T	CRF_HUMAN	Gene/Protein Processing	[10]
Cyclin-dependent kinase 4 (CDK4)	OT7EP05T	CDK4_HUMAN	Gene/Protein Processing	[8]
Cyclin-dependent kinase inhibitor 1 (CDKN1A)	OTQWHCZE	CDN1A_HUMAN	Gene/Protein Processing	[8]
Cyclin-dependent kinase inhibitor 2A (CDKN2A)	OTN0ZWAE	CDN2A_HUMAN	Gene/Protein Processing	[8]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 100).
• [2] Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat. Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4.
• [3] Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
• [4] Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur J Clin Pharmacol. 2003 May;59(1):45-50.
• [5] CYP2J2 and CYP2C19 are the major enzymes responsible for metabolism of albendazole and fenbendazole in human liver microsomes and recombinant P450 assay systems. Antimicrob Agents Chemother. 2013 Nov;57(11):5448-56.
• [6] Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol Sci. 2007 Mar;96(1):101-14.
• [7] A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005 Feb;83(2):282-92.
• [8] A gene signature-based approach identifies thioridazine as an inhibitor of phosphatidylinositol-3'-kinase (PI3K)/AKT pathway in ovarian cancer cells. Gynecol Oncol. 2011 Jan;120(1):121-7. doi: 10.1016/j.ygyno.2010.10.003. Epub 2010 Oct 29.
• [9] Identification of environmental chemicals that activate p53 signaling after in vitro metabolic activation. Arch Toxicol. 2022 Jul;96(7):1975-1987. doi: 10.1007/s00204-022-03291-5. Epub 2022 Apr 18.
• [10] Antipsychotic drugs inhibit the human corticotropin-releasing-hormone gene promoter activity in neuro-2A cells-an involvement of protein kinases. Neuropsychopharmacology. 2006 Apr;31(4):853-65. doi: 10.1038/sj.npp.1300911.
• [11] The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
• [12] Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
• [13] CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
• [14] Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
• [15] Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
• [16] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
• [17] Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
• [18] [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
• [19] Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
• [20] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [21] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [22] MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
• [23] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [24] Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
• [25] Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
• [26] Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
• [27] Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
• [28] Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
• [29] Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
• [30] CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
• [31] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [32] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [33] Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
• [34] Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
• [35] Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
• [36] Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
• [37] Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
• [38] High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
• [39] Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
• [40] Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
• [41] CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
• [42] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [43] Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
• [44] Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
• [45] A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
• [46] Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
• [47] Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
• [48] Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
• [49] The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
• [50] Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol Lett. 2016 Jan 22;241:82-94.
• [51] Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
• [52] Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
• [53] Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
• [54] Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem Biol Interact. 2004 Apr 15;147(3):331-40.
• [55] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [56] In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos. 2004 Nov;32(11):1279-86.
• [57] Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl). 2008 Apr;197(2):229-35. doi: 10.1007/s00213-007-1029-z. Epub 2007 Dec 6.
• [58] Positron emission tomography measurement of dopamine D? receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia. J Clin Psychiatry. 2010 Sep;71(9):1131-7. doi: 10.4088/JCP.08m04307yel. Epub 2010 Feb 23.
• [59] Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet Genomics. 2009 May;19(5):373-82. doi: 10.1097/FPC.0b013e328329a60f.
• [60] Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment. Pharmacogenet Genomics. 2010 Jun;20(6):359-66. doi: 10.1097/FPC.0b013e3283397d06.
• [61] A preliminary study: novelty seeking, frontal executive function, and dopamine receptor (D2) TaqI A gene polymorphism in patients with methamphetamine dependence. Compr Psychiatry. 2008 Jul-Aug;49(4):387-92. doi: 10.1016/j.comppsych.2008.01.008. Epub 2008 Mar 21.
• [62] Imaging gene-substance interactions: the effect of the DRD2 TaqIA polymorphism and the dopamine agonist bromocriptine on the brain activation during the anticipation of reward. Neurosci Lett. 2006 Sep 25;405(3):196-201. doi: 10.1016/j.neulet.2006.07.030. Epub 2006 Aug 8.
• [63] Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):11927-32. doi: 10.1073/pnas.0609752104. Epub 2007 Jul 2.
• [64] Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neurosci Lett. 2005 Mar 7;376(1):1-4. doi: 10.1016/j.neulet.2004.11.014. Epub 2004 Dec 2.
• [65] Atrial-like Engineered Heart Tissue: An In?Vitro Model of the Human Atrium. Stem Cell Reports. 2018 Dec 11;11(6):1378-1390. doi: 10.1016/j.stemcr.2018.10.008. Epub 2018 Nov 8.
• [66] Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
• [67] Expression of inwardly rectifying potassium channels (GIRKs) and beta-adrenergic regulation of breast cancer cell lines. BMC Cancer. 2004 Dec 16;4:93. doi: 10.1186/1471-2407-4-93.
• [68] The genomic response of a human uterine endometrial adenocarcinoma cell line to 17alpha-ethynyl estradiol. Toxicol Sci. 2009 Jan;107(1):40-55.
• [69] 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
• [70] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [71] Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
• [72] Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity. Eur J Drug Metab Pharmacokinet. 2011 Mar;36(1):1-16.
• [73] Inhibition of CYP2E1 catalytic activity in vitro by S-adenosyl-L-methionine. Biochem Pharmacol. 2005 Apr 1;69(7):1081-93.
• [74] Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol. 2012 Apr;28(2):69-87.
• [75] An in vitro model of human acute ethanol exposure that incorporates CXCR3- and CXCR4-dependent recruitment of immune cells. Toxicol Sci. 2013 Mar;132(1):131-41.
• [76] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [77] Proteomic analysis of hepatic effects of phenobarbital in mice with humanized liver. Arch Toxicol. 2022 Oct;96(10):2739-2754. doi: 10.1007/s00204-022-03338-7. Epub 2022 Jul 26.
• [78] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [79] In vitro inhibition of human CYP2E1 and CYP3A by quercetin and myricetin in hepatic microsomes is not gender dependent. Toxicology. 2017 Apr 15;381:10-18. doi: 10.1016/j.tox.2017.02.012. Epub 2017 Feb 21.
• [80] The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
• [81] Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci. 2006 Jul;92(1):51-60.
• [82] Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
• [83] Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
• [84] Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S.
• [85] Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019 Sep 1;310:108744. doi: 10.1016/j.cbi.2019.108744. Epub 2019 Jul 9.
• [86] Cyp2a6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans. Drug Metab Dispos. 2005 Sep;33(9):1361-6. doi: 10.1124/dmd.105.004796. Epub 2005 Jun 24.
• [87] Mimicking gene defects to treat drug dependence. Ann N Y Acad Sci. 2000;909:233-46. doi: 10.1111/j.1749-6632.2000.tb06685.x.
• [88] Expression of CYP2A6 in tumor cells augments cellular sensitivity to tegafur. Jpn J Cancer Res. 2001 May;92(5):524-8. doi: 10.1111/j.1349-7006.2001.tb01125.x.
• [89] CYP1A1/1B1 and CYP2A6/2A13 activity is conserved in cultures of differentiated primary human tracheobronchial epithelial cells. Toxicol In Vitro. 2011 Jun;25(4):922-9.
• [90] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [91] Measurement of 4-hydroxylation of ifosfamide in human liver microsomes using the estimation of free and protein-bound acrolein and codetermination of keto- and carboxyifosfamide. J Cancer Res Clin Oncol. 2002 Jul;128(7):385-92.
• [92] Integrated 'omics analysis reveals new drug-induced mitochondrial perturbations in human hepatocytes. Toxicol Lett. 2018 Jun 1;289:1-13.
• [93] Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes. Xenobiotica. 2009 Nov;39(11):795-802. doi: 10.3109/00498250903171395.
• [94] A novel single nucleotide polymorphism altering stability and activity of CYP2a6. Biochem Biophys Res Commun. 2001 Mar 2;281(3):810-4. doi: 10.1006/bbrc.2001.4422.
• [95] Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos. 2003 Apr;31(4):439-46.
• [96] Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. Xenobiotica. 2004 May;34(5):429-38.
• [97] The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. Life Sci. 2006 Nov 25;79(26):2432-40.
• [98] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [99] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [100] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [101] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [102] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [103] In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies. Toxicol Sci. 2007 Sep;99(1):162-73.
• [104] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [105] Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
• [106] Oxidative Stress Alters miRNA and Gene Expression Profiles in Villous First Trimester Trophoblasts. Biomed Res Int. 2015;2015:257090. doi: 10.1155/2015/257090. Epub 2015 Aug 3.
• [107] Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
• [108] Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
• [109] Effects of aspirin on metastasis-associated gene expression detected by cDNA microarray. Acta Pharmacol Sin. 2004 Oct;25(10):1327-33.
• [110] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [111] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [112] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [113] Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. Chem Biol Interact. 2009 Apr 15;179(1):17-24.
• [114] Kinetic analysis of the liver-type (GLUT2) and brain-type (GLUT3) glucose transporters in Xenopus oocytes: substrate specificities and effects of transport inhibitors. Biochem J. 1993 Mar 15;290 ( Pt 3)(Pt 3):701-6. doi: 10.1042/bj2900701.
• [115] Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
• [116] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [117] Retinoic acid represses a cassette of candidate pluripotency chromosome 12p genes during induced loss of human embryonal carcinoma tumorigenicity. Biochim Biophys Acta. 2005 Oct 15;1731(1):48-56. doi: 10.1016/j.bbaexp.2005.08.006. Epub 2005 Sep 1.
• [118] Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
• [119] Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
• [120] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [121] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [122] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [123] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [124] An approach to elucidate potential mechanism of renal toxicity of arsenic trioxide. Exp Hematol. 2007 Feb;35(2):252-62.
• [125] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [126] Unique signatures of stress-induced senescent human astrocytes. Exp Neurol. 2020 Dec;334:113466. doi: 10.1016/j.expneurol.2020.113466. Epub 2020 Sep 17.
• [127] Folate deficiency in normal human fibroblasts leads to altered expression of genes primarily linked to cell signaling, the cytoskeleton and extracellular matrix. J Nutr Biochem. 2007 Aug;18(8):541-52. doi: 10.1016/j.jnutbio.2006.11.002. Epub 2007 Feb 22.
• [128] Differentiation of human embryonic stem cells into smooth muscle cells in adherent monolayer culture. Biochem Biophys Res Commun. 2006 Dec 15;351(2):321-7. doi: 10.1016/j.bbrc.2006.09.171. Epub 2006 Oct 17.
• [129] Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma. Mol Cancer Ther. 2007 Jan;6(1):70-81. doi: 10.1158/1535-7163.MCT-06-0125.
• [130] ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
• [131] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [132] Inhibiting Heat Shock Proteins Can Potentiate the Cytotoxic Effect of Cannabidiol in Human Glioma Cells. Anticancer Res. 2015 Nov;35(11):5827-37.
• [133] Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. J Cell Biochem. 2006 Aug 1;98(5):1163-84.
• [134] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [135] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [136] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [137] Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
• [138] MS4A3-HSP27 target pathway reveals potential for haematopoietic disorder treatment in alimentary toxic aleukia. Cell Biol Toxicol. 2023 Feb;39(1):201-216. doi: 10.1007/s10565-021-09639-4. Epub 2021 Sep 28.
• [139] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [140] Adaptive homeostasis of the vitamin D-vitamin D nuclear receptor axis in 8-methoxypsoralen-induced hepatotoxicity. Toxicol Appl Pharmacol. 2019 Jan 1;362:150-158. doi: 10.1016/j.taap.2018.11.002. Epub 2018 Nov 10.
• [141] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [142] Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
• [143] Farnesoid X receptor induces murine scavenger receptor Class B type I via intron binding. PLoS One. 2012;7(4):e35895. doi: 10.1371/journal.pone.0035895. Epub 2012 Apr 23.
• [144] The methyl transferase PRMT1 functions as co-activator of farnesoid X receptor (FXR)/9-cis retinoid X receptor and regulates transcription of FXR responsive genes. Mol Pharmacol. 2005 Aug;68(2):551-8. doi: 10.1124/mol.105.012104. Epub 2005 May 23.
• [145] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [146] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [147] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [148] Verapamil-induced hyperprolactinemia complicated by a pituitary incidentaloma. Ann Pharmacother. 1995 Oct;29(10):999-1001. doi: 10.1177/106002809502901009.
• [149] [Impotence and gynecomastia secondary to hyperprolactinemia induced by ranitidine]. Therapie. 1994 Jul-Aug;49(4):361-2.
• [150] Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release. Mol Cell Endocrinol. 2005 Jul 15;239(1-2):27-36. doi: 10.1016/j.mce.2005.04.008.
• [151] Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease. Brain. 2009 Feb;132(Pt 2):392-401. doi: 10.1093/brain/awn326. Epub 2009 Jan 19.
• [152] Influence of naloxone on muscle sympathetic nerve activity, systemic and calf haemodynamics and ambulatory blood pressure after exercise in mild essential hypertension. J Hypertens. 1995 Apr;13(4):447-61.
• [153] The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials. J Affect Disord. 2009 May;115(1-2):18-26. doi: 10.1016/j.jad.2008.12.017. Epub 2009 Feb 23.
• [154] Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine. J Clin Psychiatry. 2006 Jun;67(6):952-7. doi: 10.4088/jcp.v67n0612.
• [155] Massive breast enlargement in a patient receiving D-penicillamine for systemic sclerosis. J Rheumatol. 1985 Oct;12(5):990-1.
• [156] Hyperprolactinaemia induced by proton pump inhibitor. J Pak Med Assoc. 2010 Aug;60(8):689-90.
• [157] p53-R175H mutant gains new function in regulation of doxorubicin-induced apoptosis. Int J Cancer. 2005 Apr 10;114(3):331-6. doi: 10.1002/ijc.20818.
• [158] Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line. Toxicol Appl Pharmacol. 2006 Oct 1;216(1):89-97. doi: 10.1016/j.taap.2006.04.015. Epub 2006 May 19.
• [159] Quantitative analysis of gene expression changes in response to genotoxic compounds. Toxicol In Vitro. 2017 Mar;39:15-28. doi: 10.1016/j.tiv.2016.11.004. Epub 2016 Nov 5.
• [160] Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res. 2000;12(9-10):397-408. doi: 10.3727/096504001108747855.
• [161] Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line. J Biochem Mol Toxicol. 2021 Feb;35(2):e22638. doi: 10.1002/jbt.22638. Epub 2020 Oct 1.
• [162] Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage. Nucleic Acids Res. 2009 Jan;37(1):78-95. doi: 10.1093/nar/gkn910. Epub 2008 Nov 16.
• [163] Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells. Oncotarget. 2019 Jan 1;10(1):45-59. doi: 10.18632/oncotarget.26534. eCollection 2019 Jan 1.
• [164] Nitrogen Mustard Alkylates and Cross-Links p53 in Human Keratinocytes. Chem Res Toxicol. 2022 Apr 18;35(4):636-650. doi: 10.1021/acs.chemrestox.1c00420. Epub 2022 Mar 21.
• [165] Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex. Br J Cancer. 2013 Nov 12;109(10):2751-62. doi: 10.1038/bjc.2013.583. Epub 2013 Oct 29.
• [166] Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
• [167] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [168] Terbutaline inhibits corticotropin-releasing hormone (CRH) expression in human trophoblast cells. J Matern Fetal Neonatal Med. 2006 Nov;19(11):735-9. doi: 10.1080/14767050600886724.
• [169] Peroxisome proliferator activated receptor gamma (PPAR-gama) ligand pioglitazone regulated gene networks in term human primary trophoblast cells. Reprod Toxicol. 2018 Oct;81:99-107.
• [170] p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. Neuro Oncol. 2012 Jul;14(7):870-81. doi: 10.1093/neuonc/nos114. Epub 2012 Jun 18.
• [171] In vitro effects of cannabidiol and its main metabolites in mouse and human Sertoli cells. Food Chem Toxicol. 2022 Jan;159:112722. doi: 10.1016/j.fct.2021.112722. Epub 2021 Dec 3.
• [172] Selenite and selenomethionine promote HL-60 cell cycle progression. J Nutr. 2002 Apr;132(4):674-9. doi: 10.1093/jn/132.4.674.
• [173] JNK1 is required for sulindac-mediated inhibition of cell proliferation and induction of apoptosis in vitro and in vivo. Eur J Pharmacol. 2007 Apr 10;560(2-3):95-100. doi: 10.1016/j.ejphar.2007.01.020. Epub 2007 Jan 19.
• [174] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [175] Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. Int J Mol Med. 2010 Nov;26(5):735-41. doi: 10.3892/ijmm_00000520.
• [176] Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin Diagn Lab Immunol. 2004 Jan;11(1):63-9. doi: 10.1128/cdli.11.1.63-69.2004.
• [177] Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status. Mol Biol Rep. 2008 Sep;35(3):421-9.
• [178] The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate beta-catenin/TCF-4 signaling. Oncogene. 2001 Feb 1;20(5):645-53. doi: 10.1038/sj.onc.1204123.
• [179] Novel mechanism of cannabidiol-induced apoptosis in breast cancer cell lines. Breast. 2018 Oct;41:34-41. doi: 10.1016/j.breast.2018.06.009. Epub 2018 Jun 22.
• [180] -Carotene Induces Apoptosis in Human Esophageal Squamous Cell Carcinoma Cell Lines via the Cav-1/AKT/NF-B Signaling Pathway. J Biochem Mol Toxicol. 2016 Mar;30(3):148-57. doi: 10.1002/jbt.21773. Epub 2016 Jan 6.
• [181] Cross-talk between non-genomic and genomic signalling pathways--distinct effect profiles of environmental estrogens. Toxicol Appl Pharmacol. 2010 Jun 1;245(2):160-70. doi: 10.1016/j.taap.2010.02.015. Epub 2010 Mar 4.
• [182] Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006 Jun 1;66(11):5542-8. doi: 10.1158/0008-5472.CAN-05-4620.
• [183] BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile. J Biochem Mol Toxicol. 2019 May;33(5):e22286. doi: 10.1002/jbt.22286. Epub 2019 Jan 23.
• [184] Resveratrol attenuates senescence of adipose-derived mesenchymal stem cells and restores their paracrine effects on promoting insulin secretion of INS-1 cells through Pim-1. Eur Rev Med Pharmacol Sci. 2016;20(6):1203-13.
• [185] Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation. J Biochem Mol Toxicol. 2018 Jan;32(1). doi: 10.1002/jbt.22007. Epub 2017 Nov 7.
• [186] Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther. 2001 Sep;298(3):976-85.
• [187] Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
• [188] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [189] Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
• [190] Melanoma coordinates general and cell-specific mechanisms to promote methotrexate resistance. Exp Cell Res. 2012 Jun 10;318(10):1146-59.
• [191] Activation of the p38 MAPK/Akt/ERK1/2 signal pathways is required for the protein stabilization of CDC6 and cyclin D1 in low-dose arsenite-induced cell proliferation. J Cell Biochem. 2010 Dec 15;111(6):1546-55. doi: 10.1002/jcb.22886.
• [192] Lunasin, a novel seed peptide, sensitizes human breast cancer MDA-MB-231 cells to aspirin-arrested cell cycle and induced apoptosis. Chem Biol Interact. 2010 Jul 30;186(2):127-34. doi: 10.1016/j.cbi.2010.04.027. Epub 2010 May 21.
• [193] Vitamin D receptor as a master regulator of the c-MYC/MXD1 network. Proc Natl Acad Sci U S A. 2012 Nov 13;109(46):18827-32. doi: 10.1073/pnas.1210037109. Epub 2012 Oct 29.
• [194] Inter-laboratory comparison of human renal proximal tubule (HK-2) transcriptome alterations due to Cyclosporine A exposure and medium exhaustion. Toxicol In Vitro. 2009 Apr;23(3):486-99.
• [195] Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. Mutagenesis. 2005 Mar;20(2):139-46. doi: 10.1093/mutage/gei019. Epub 2005 Mar 22.
• [196] Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
• [197] Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. Cancer Res. 2002 Aug 1;62(15):4419-26.
• [198] Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells. Toxicol Appl Pharmacol. 2017 Nov 15;335:16-27. doi: 10.1016/j.taap.2017.09.017. Epub 2017 Sep 21.
• [199] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [200] Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol. 2009 Mar;160(3):519-26. doi: 10.1111/j.1365-2133.2008.08931.x. Epub 2008 Nov 25.
• [201] Glucocorticoids induce G1 arrest of lymphoblastic cells through retinoblastoma protein Rb1 dephosphorylation in childhood acute lymphoblastic leukemia in vivo. Cancer Biol Ther. 2004 May;3(5):470-6. doi: 10.4161/cbt.3.5.838. Epub 2004 May 9.
• [202] Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
• [203] Different apoptosis ratios and gene expressions in two human cell lines after sevoflurane anaesthesia. Acta Anaesthesiol Scand. 2009 Oct;53(9):1192-9. doi: 10.1111/j.1399-6576.2009.02036.x. Epub 2009 Jun 30.
• [204] [Mechanisms underlying the effect of arsenic trioxide on proliferation inhibition and apoptosis induction in myeloma cell line u266]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Oct;15(5):982-5.
• [205] Lovastatin lactone elicits human lung cancer cell apoptosis via a COX-2/PPAR-dependent pathway. Oncotarget. 2016 Mar 1;7(9):10345-62. doi: 10.18632/oncotarget.7213.
• [206] Comparison of burst of reactive oxygen species and activation of caspase-3 in apoptosis of K562 and HL-60 cells induced by docetaxel. Cancer Lett. 2004 Oct 8;214(1):103-13. doi: 10.1016/j.canlet.2004.03.047.
• [207] Induction of mitochondrial manganese superoxide dismutase confers resistance to apoptosis in acute myeloblastic leukaemia cells exposed to etoposide. Br J Haematol. 2000 Mar;108(3):574-81. doi: 10.1046/j.1365-2141.2000.01852.x.
• [208] Cisplatin-enhanced sensitivity of glioblastoma multiforme U251 cells to adenovirus-delivered TRAIL in vitro. Tumour Biol. 2010 Dec;31(6):613-22. doi: 10.1007/s13277-010-0077-x. Epub 2010 Jul 11.
• [209] Insulin-like growth factor I is the key growth factor in serum that protects neuroblastoma cells from hyperosmotic-induced apoptosis. J Cell Physiol. 2000 Jan;182(1):24-32. doi: 10.1002/(SICI)1097-4652(200001)182:1<24::AID-JCP3>3.0.CO;2-6.
• [210] mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin. Biol Chem. 2004 Nov;385(11):1099-103. doi: 10.1515/BC.2004.143.
• [211] Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-B axis: Shedding new light on resistance to Aprepitant. Int J Biochem Cell Biol. 2018 Oct;103:105-114. doi: 10.1016/j.biocel.2018.08.010. Epub 2018 Aug 23.
• [212] Quercetin potentiates apoptosis by inhibiting nuclear factor-kappaB signaling in H460 lung cancer cells. Biol Pharm Bull. 2013;36(6):944-51. doi: 10.1248/bpb.b12-01004.
• [213] Expression of the helix-loop-helix protein inhibitor of DNA binding-1 (ID-1) is activated by all-trans retinoic acid in normal human keratinocytes. Toxicol Appl Pharmacol. 2006 Aug 1;214(3):219-29. doi: 10.1016/j.taap.2005.12.015. Epub 2006 Feb 21.
• [214] [Re-expression of p16 gene in myeloma cell line U266 by arsenic trioxide]. Ai Zheng. 2004 Jun;23(6):626-30.
• [215] p16 loss facilitate hydroquinone-induced malignant transformation of TK6 cells through promoting cell proliferation and accelerating the cell cycle progression. Environ Toxicol. 2021 Aug;36(8):1591-1599. doi: 10.1002/tox.23155. Epub 2021 May 1.
• [216] Delta 9-tetrahydrocannabinol inhibits cell cycle progression by downregulation of E2F1 in human glioblastoma multiforme cells. Acta Oncol. 2008;47(6):1062-70.
• [217] Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology. 2005 Apr;74(1):31-6. doi: 10.1159/000083234. Epub 2005 Jan 7.
• [218] Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005 Jan;16(1):54-8. doi: 10.1046/j.1540-8167.2005.04470.x.
• [219] Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev Technol. 2004 Oct;2(5):497-506. doi: 10.1089/adt.2004.2.497.
• [220] Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.
• [221] Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol. 2008 Nov;155(6):957-66. doi: 10.1038/bjp.2008.325. Epub 2008 Aug 25.
• [222] Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy. Br J Pharmacol. 2006 Mar;147(6):642-52. doi: 10.1038/sj.bjp.0706508.
• [223] Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol. 1999 Mar;359(3):212-9. doi: 10.1007/pl00005344.
• [224] Redox state dependency of HERGS631C channel pharmacology: relation to C-type inactivation. FEBS Lett. 2000 May 26;474(1):111-5. doi: 10.1016/s0014-5793(00)01586-6.
• [225] Frenolicin B Targets Peroxiredoxin 1 and Glutaredoxin 3 to Trigger ROS/4E-BP1-Mediated Antitumor Effects. Cell Chem Biol. 2019 Mar 21;26(3):366-377.e12. doi: 10.1016/j.chembiol.2018.11.013. Epub 2019 Jan 17.
• [226] Benzodithiophenes potentiate differentiation of acute promyelocytic leukemia cells by lowering the threshold for ligand-mediated corepressor/coactivator exchange with retinoic acid receptor alpha and enhancing changes in all-trans-retinoic acid-regulated gene expression. Cancer Res. 2005 Sep 1;65(17):7856-65. doi: 10.1158/0008-5472.CAN-05-1056.
• [227] Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation. Tumour Biol. 2015 Apr;36(4):2323-34. doi: 10.1007/s13277-014-2839-3. Epub 2014 Nov 22.
• [228] Androgen receptor-mTOR crosstalk is regulated by testosterone availability: implication for prostate cancer cell survival. Anticancer Res. 2010 Oct;30(10):3895-901.
• [229] A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia. Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3378-83.
• [230] The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):124-34.
• [231] The acute EPS of haloperidol may be unrelated to its metabolic transformation to BCPP+. Bioorg Med Chem Lett. 2003 Nov 3;13(21):3779-82. doi: 10.1016/j.bmcl.2003.07.015.
• [232] Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant. Pharmacogenomics J. 2010 Jun;10(3):200-18. doi: 10.1038/tpj.2009.65. Epub 2009 Dec 22.
• [233] A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms. Pharmacogenomics J. 2009 Dec;9(6):404-10. doi: 10.1038/tpj.2009.26. Epub 2009 Jun 9.
• [234] Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
• [235] Striatal dopamine d2/d3 receptor availability is reduced in methamphetamine dependence and is linked to impulsivity. J Neurosci. 2009 Nov 25;29(47):14734-40. doi: 10.1523/JNEUROSCI.3765-09.2009.
• [236] Lower level of endogenous dopamine in patients with cocaine dependence: findings from PET imaging of D(2)/D(3) receptors following acute dopamine depletion. Am J Psychiatry. 2009 Oct;166(10):1170-7. doi: 10.1176/appi.ajp.2009.08121801. Epub 2009 Sep 1.
• [237] Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine. Int J Neurosci. 2005 Nov;115(11):1539-47. doi: 10.1080/00207450590957863.
• [238] Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95.
• [239] Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
• [240] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [241] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [242] Association analysis of the DRD4 and COMT genes in methamphetamine abuse. Am J Med Genet B Neuropsychiatr Genet. 2004 Aug 15;129B(1):120-4. doi: 10.1002/ajmg.b.30024.
• [243] Polymorphisms TaqI A of the DRD2, BalI of the DRD3, exon III repeat of the DRD4, and 3' UTR VNTR of the DAT: association with childhood ADHD in male African-Caribbean cocaine dependents?. Am J Med Genet B Neuropsychiatr Genet. 2007 Dec 5;144B(8):1034-41. doi: 10.1002/ajmg.b.30540.